PMC8121169_01
Clinical images of the right eye (A,C,E,G) and left eye (B,D,F,H) of a 2-year-old domestic shorthair cat diagnosed with severe bilateral eosinophilic keratitis, managed with combined immunosuppressive therapy (subcutaneous triamcinolone acetonide and topical 0.5% tacrolimus), and examined on Day 0 (A,B), Day 11 (C,D), Day 38 (E,F), and Day 101 (G,H).
fvets-08-580396-g0001.jpg
PMC8121169_01_fvets-08-580396-g0001.jpg
F1
OU, in addition to white raised plaques present on the corneal surface OU (masked by the third eyelid OD) (Figures 1A,B). Ocular diagnostic testing showed that intraocular pressures (TonoVet, Jorgensen Laboratories) were normal (23 mmHg OD, 24 mmHg OS), Schirmer tear test-1 (Merck Animal Health) results were normal (16 mm/min OD, 19 mm/min OS), and multifocal punctate areas of fluorescein uptake were noted OU. Keratitis was greatly improved with resolution of corneal plaques and epithelial defects OU (no fluorescein uptake), as well as marked reduction in the fibrovascular ingrowth (mild residual corneal vascularization) allowing for clear visualization of the inside of the eye OU (Figures 1C,D). OU (Figures 1E,F). Only thin superficial vessels were present in the cornea OU, most of which were hypoperfused ("ghost" vessels). The recheck visit confirmed resolution of ocular signs OU with only few hypoperfused superficial corneal vessels noticed on retro-illumination (Figures 1G,H).
Cytological specimen of the left corneal surface (Wright Giemsa stain) highlighting a mixed, predominantly eosinophilic inflammation (black arrowheads) with few mast cells and lymphocytes. Bar = 40 mum (top right insert) or 100 mum (background image).
fvets-08-580396-g0002.jpg
PMC8121169_01_fvets-08-580396-g0002.jpg
F2
Cytological evaluation of the white corneal plaques revealed a mixed, predominately eosinophilic inflammation with few mast cells and lymphocytes (Figure 2).
Clinical images of the right eye (A) and left eye (B) of a cat with historical eosinophilic keratitis in clinical remission. Images were taken by the owner using a smartphone on Day 374 following initial diagnosis, that is, 278 days after discontinuation of all therapies.
fvets-08-580396-g0003.jpg
PMC8121169_01_fvets-08-580396-g0003.jpg
F3
The latest follow-up at time of manuscript writing was Day 374 (Figures 3, 4).
Timeline of the cat's clinical course and treatments.
fvets-08-580396-g0004.jpg
PMC8121169_01_fvets-08-580396-g0004.jpg
F4
The latest follow-up at time of manuscript writing was Day 374 (Figures 3, 4).